BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11048371)

  • 21. [Parameters of PSA fractions in early diagnosis of prostatic cancer in healthy males over 50].
    Loran OB; Krokhotina LV; Pushkar' DIu; Valiev AZ; Rasner PI
    Urol Nefrol (Mosk); 1999; (1):19-21. PubMed ID: 11149339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate specific antigen based prostate cancer screening: accumulating evidence of efficacy but persistent uncertainty.
    Andriole GL
    J Urol; 2005 Aug; 174(2):413-4. PubMed ID: 16006854
    [No Abstract]   [Full Text] [Related]  

  • 23. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prostate-specific antigen (PSA)].
    Huland H
    Urologe A; 1995 Jul; 34(4):273-4. PubMed ID: 7545840
    [No Abstract]   [Full Text] [Related]  

  • 25. Counselling patients before rectal examination.
    Bhanot S
    Hosp Med; 2002 Jun; 63(6):374. PubMed ID: 12096674
    [No Abstract]   [Full Text] [Related]  

  • 26. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F
    Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing the diagnosis of prostate cancer in high-risk men: the supplementary biomarker approach.
    Kommu S; Persad R; Watkin N; Boyd PJ; Eeles R
    BJU Int; 2005 Jan; 95(1):5-7. PubMed ID: 15638884
    [No Abstract]   [Full Text] [Related]  

  • 30. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer.
    Galić J; Karner I; Cenan L; Tucak A; Hegedus I; Pasini J; Bilandzija-Peranović M; Mihaljević S
    Coll Antropol; 2003; 27 Suppl 1():61-6. PubMed ID: 12955893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low prostate specific antigen levels and normal digital rectal examination--a report on a follow up cohort in general practice.
    Brett T
    Aust Fam Physician; 2005 Apr; 34(4):301-2. PubMed ID: 15861761
    [No Abstract]   [Full Text] [Related]  

  • 33. Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.
    Nam RK; Toi A; Trachtenberg J; Klotz LH; Jewett MA; Emami M; Sugar L; Sweet J; Pond GR; Narod SA
    J Urol; 2006 Feb; 175(2):489-94. PubMed ID: 16406978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prostate cancer].
    Uchida K; Akaza H
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1469-74. PubMed ID: 11681260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 36. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
    Eggener SE; Roehl KA; Catalona WJ
    J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.
    Pelzer A; Bektic J; Berger AP; Pallwein L; Halpern EJ; Horninger W; Bartsch G; Frauscher F
    J Urol; 2005 Jun; 173(6):1926-9. PubMed ID: 15879783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An elevated PSA, which normalizes, does not exclude the presence of prostate cancer.
    Boddy JL; Pike DJ; Al-Hayek S; Shaida N; Malone PR
    Prostate Cancer Prostatic Dis; 2005; 8(4):349-52. PubMed ID: 16010283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guidelines on the management of prostate cancer. A document for local expert groups in the United Kingdom preparing prostate management policy documents.
    ;
    BJU Int; 1999 Dec; 84(9):987-1014. PubMed ID: 10571625
    [No Abstract]   [Full Text] [Related]  

  • 40. High result in prostate specific antigen test.
    Mokete M; Palmer AR; O'Flynn KJ
    BMJ; 2003 Aug; 327(7411):379. PubMed ID: 12919991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.